인투셀

287840KOSDAQSector: Pharma & Biotech

₩19,770▼ 3.56%Market cap ₩297.0BAs of Jul 21, 2026 close · updated once daily

Grade D31.3 ptsTop 84% of 2,523 stocks

Financial strength

37.8

Growth momentum

26.5

Price attractiveness

27.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

37.8

How much debt does it carry relative to equity?

Debt-to-equity ratio

66.7%

✗ Below median · Top 62.4% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

970.9%

✓ Above median · Top 14.8% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-448.0%

✗ Below median · Top 90.7% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-42.8%

✗ Below median · Top 81.1% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Growth momentum

26.5

How much did revenue grow in a year?

Revenue growth (YoY)

-20.9%

✗ Below median · Top 88.8% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

-5.2%

✗ Below median · Top 58.3% in sector

Sector median 3.6%

Source filing: annual report (separate) — view original ↗

Price attractiveness

27.3

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 57.1% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

12.00x

✗ Below median · Top 88.4% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15